Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Consensus Rating of “Buy” from Brokerages

Definium Therapeutics, Inc. (NASDAQ:DFTX) has earned an average rating of “Buy” from the seventeen ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $49.2308.

A number of brokerages recently issued reports on DFTX. Canaccord Genuity Group set a $58.00 price target on Definium Therapeutics and gave the company a “buy” rating in a report on Tuesday, June 30th. Leerink Partners set a $52.00 price objective on Definium Therapeutics and gave the stock an “outperform” rating in a report on Monday, June 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Tuesday, April 21st. Royal Bank Of Canada reiterated an “outperform” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Finally, Wall Street Zen downgraded Definium Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday.

Insider Buying and Selling at Definium Therapeutics

In other Definium Therapeutics news, CFO Brandi Roberts sold 3,013 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the transaction, the chief financial officer owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. This trade represents a 1.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Matthew T. Wiley sold 2,867 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $129,101.01. Following the completion of the sale, the insider owned 174,633 shares of the company’s stock, valued at approximately $7,863,723.99. This represents a 1.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 48,096 shares of company stock valued at $2,165,763 in the last ninety days. 2.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Definium Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. lifted its holdings in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after buying an additional 2,003 shares during the period. BNP Paribas Financial Markets raised its position in shares of Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after acquiring an additional 3,020 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of Definium Therapeutics in the 3rd quarter worth $107,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Definium Therapeutics during the 4th quarter worth $117,000. Finally, Caxton Associates LLP purchased a new stake in shares of Definium Therapeutics during the 3rd quarter worth $126,000. 27.91% of the stock is currently owned by institutional investors.

Definium Therapeutics Trading Up 0.4%

DFTX stock opened at $44.29 on Tuesday. The company has a market capitalization of $4.42 billion, a PE ratio of -17.79 and a beta of 2.20. Definium Therapeutics has a 12 month low of $7.96 and a 12 month high of $49.20. The firm’s 50-day moving average is $31.43 and its 200 day moving average is $22.77. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.69 and a quick ratio of 4.69.

Definium Therapeutics (NASDAQ:DFTX) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.23). On average, research analysts anticipate that Definium Therapeutics will post -2.27 EPS for the current year.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.